Below are the most recent publications written about "Anticarcinogenic Agents" by people in Profiles.
-
Patterson AD, Gonzalez FJ, Perdew GH, Peters JM. Molecular Regulation of Carcinogenesis: Friend and Foe. Toxicol Sci. 2018 10 01; 165(2):277-283.
-
Song Y, Manson JE, Lee IM, Cook NR, Paul L, Selhub J, Giovannucci E, Zhang SM. Effect of combined folic acid, vitamin B(6), and vitamin B(12) on colorectal adenoma. J Natl Cancer Inst. 2012 Oct 17; 104(20):1562-75.
-
Mercier I, Camacho J, Titchen K, Gonzales DM, Quann K, Bryant KG, Molchansky A, Milliman JN, Whitaker-Menezes D, Sotgia F, Jasmin JF, Schwarting R, Pestell RG, Blagosklonny MV, Lisanti MP. Caveolin-1 and accelerated host aging in the breast tumor microenvironment: chemoprevention with rapamycin, an mTOR inhibitor and anti-aging drug. Am J Pathol. 2012 Jul; 181(1):278-93.
-
Sharma C, Nusri Qel-A, Begum S, Javed E, Rizvi TA, Hussain A. (-)-Epigallocatechin-3-gallate induces apoptosis and inhibits invasion and migration of human cervical cancer cells. Asian Pac J Cancer Prev. 2012; 13(9):4815-22.
-
Fagerlin A, Dillard AJ, Smith DM, Zikmund-Fisher BJ, Pitsch R, McClure JB, Greene S, Alford SH, Nair V, Hayes DF, Wiese C, Ubel PA. Women's interest in taking tamoxifen and raloxifene for breast cancer prevention: response to a tailored decision aid. Breast Cancer Res Treat. 2011 Jun; 127(3):681-8.
-
Trufant JW, Kreizenbeck GM, Carlson KR, Muthusamy V, Girardi M, Bosenberg MW. A transient epidermolysis bullosa simplex-like phenotype associated with bexarotene treatment in a G138E KRT5 heterozygote. J Cutan Pathol. 2010 Nov; 37(11):1155-60.
-
Puli S, Jain A, Lai JC, Bhushan A. Effect of combination treatment of rapamycin and isoflavones on mTOR pathway in human glioblastoma (U87) cells. Neurochem Res. 2010 Jul; 35(7):986-93.
-
Blask DE, Dauchy RT, Brainard GC, Hanifin JP. Circadian stage-dependent inhibition of human breast cancer metabolism and growth by the nocturnal melatonin signal: consequences of its disruption by light at night in rats and women. Integr Cancer Ther. 2009 Dec; 8(4):347-53.
-
Zimmers TA, Gutierrez JC, Koniaris LG. Loss of GDF-15 abolishes sulindac chemoprevention in the ApcMin/+ mouse model of intestinal cancer. J Cancer Res Clin Oncol. 2010 Apr; 136(4):571-6.
-
Bility MT, Zhu B, Kang BH, Gonzalez FJ, Peters JM. Ligand activation of peroxisome proliferator-activated receptor-beta/delta and inhibition of cyclooxygenase-2 enhances inhibition of skin tumorigenesis. Toxicol Sci. 2010 Jan; 113(1):27-36.